Amazingly, IL-2/IL-12/IL-18-exposed γδ T cells produce IFN-γ, and express cytotoxins and FasL, resulting in potent anti-tumoral activity comparable to that of TCR-stimulated counterparts, as shown for different E:T ratios during a 96-h monitoring period towards three tested tumor cell lines (Figure 5); Anti-tumoral activity of bypass stimulated γδ T cells comes along with insignificantly changed NKG2D expression, thus excluding an enhanced anti-tumor activity of TCR-bypass stimulated γδ T cells via this receptor. The gene discussed is IL18; the disease is neoplasm.